Clinical Development of LPRI-CF113 for Dysmenorrhea

An individual pharmaceutical development project to initiate a Phase I/II clinical trial of LPRI-CF113, the drospirenone formulation brought in for development, for the treatment of dysmenorrhea.

Companies1How many companies write about this.

Threads1One company can carry more than one thread here.

PeriodFY2025 →Last written FY2025

Directionhelps1 helps · 0 hurts · 0 flat

Loading